Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jerry Parrott, Jonathan Drachman, Eric Sievers, Christoph Franz, Franz Humer

Premium

BioMarker Strategies has appointed Jerry Parrott as its new president, CEO, and director, effective immediately. Parrott, formerly VP of corporate communications and public policy at Human Genome Sciences, will report to Jack Davis, head of BioMarker Strategies' board of directors.

Parrott also served as chairman and president of the Maryland Health Care Product Development Corporation and held various senior level positions with Bristol-Myers Squibb, American Hospital Supply Corporation, and Walgreen Company.


Seattle Genetics this week announced that Jonathan Drachman has been promoted to chief medical officer and executive VP of research and development. Additionally, Seattle Genetics promoted Eric Sievers to senior VP of clinical development.

Drachman has been a member of Seattle Genetics' management team since joining the company in 2004. Before that he was an associate professor in the hematology division at the University of Washington in Seattle where he still works as a clinical associate professor of medicine.

Sievers came to Seattle Genetics in 2006, and was involved in the clinical development for the drug Adcetris. Previously, Sievers was medical director at Zymogenetics, which was acquired by Bristol-Myers Squibb in 2010.


Roche has nominated Christoph Franz to be chairman of the board of directors. He will succeed Franz Humer, who announced that he would not stand for re-election. Franz will not renew his contract as CEO of Lufthansa Group, which expires on May 31, 2014.


Good Start Genetics has appointed Mark Adams to the position of chief information officer. Adams joins Good Start from Bridgewater Associates and was previously a principal with Booz Allen Hamilton, where he developed a biomedical informatics consulting practice. He has also been vice president of bioinformatics at Variagenics, and held positions at Incyte.



Marc Lalande
has been appointed to the new position of executive director of Genomics and Personalized Medicine Programs at the University of Connecticut where he will help lead the development of research and training programs for the Institute of Systems Genomics, as well as direct collaborations with The Jackson Laboratory for Genomic Medicine, and industry and government partnerships for the planned CT Institute for Medical Innovation and Applied Health Care Economics.

Lalande will maintain his current positions as the Health Net professor and chairman of the Department of Genetics and Developmental Biology and director of both the University of Connecticut Stem Cell Institute and the Institute for Systems Genomics. He will step down from his position as senior associate dean for research planning and coordination at the UConn School of Medicine.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more